Maximum quantity allowed is 999
请选择数量
CAS RN: 475207-59-1 | 产品编码: N1229
Sorafenib Tosylate
×
![]()
×
纯度/分析方法: >98.0%(T)(HPLC)
别名：
- 甲苯磺酸索拉非尼
- 4-[4-[3-[4-氯-3-(三氟甲基)苯基]脲基]苯氧基}-N-甲基吡啶酰胺4-甲基苯磺酸盐
- 4-[4-[[4-氯-3-(三氟甲基)苯基]氨基甲酰胺基]苯氧基]-N-甲基-2-吡啶甲酰胺4-甲基苯磺酸盐
- 4-[4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]-N-methylpicolinamide 4-Methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamamido]phenoxy]-N-methyl-2-pyridinecarboxamide 4-Methylbenzenesulfonate
产品文档：
| 规格 | 单价 | 同一天 | 2-3个工作日 | 数量 |
|---|---|---|---|---|
| 1G |
S$123.00
|
3 | 34 |
|
| 产品编码 | N1229 |
| 纯度/分析方法 | >98.0%(T)(HPLC) |
| 分子式/分子量 | C__2__1H__1__6ClF__3N__4O__3.C__7H__8O__3S = 637.03 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷藏 (0-10°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 475207-59-1 |
| Reaxys-RN | 11116227 |
| MDL编号 | MFCD08235032 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 224 °C |
GHS
| 象形图 |
|
| 信号词 | Danger |
| 危险性说明 | H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
相关法规
| RTECS# | US4588880 |
运输信息
| HS编码* | 2933.39-000 |
应用
Sorafenib Tosylate: An Orally Active Multikinase Inhibitor
Sorafenib tosylate (BAY 43-9006) is an orally active multikinase inhibitor that decrease tumor cell proliferation. There are reports that sorafenib is shown to inhibits cell surface tyrosine kinase receptors (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß: platelet-derived growth factor receptor-β) and downstream intracellular serine/threonine kinases (c-CRAF, BRAF and mutant BRAF) in vitro.1-3) Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis.4,5) In clinical, sorafenib tosylate is used for the treatment of renal cell carcinoma and hepatocellular carcinoma. (The product is for research purpose only.)
References
- 1) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- 2) Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
- 3) BAY 43-9006 Inhibition of Oncogenic RET Mutants
- F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, M. Santoro, J. Natl. Cancer Inst. 2006, 98, 326.
- 4) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (a review)
- 5) Sorafenib: a review of its use in advanced hepatocellular carcinoma
- 6) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。